Arch Therapeutics (OTCMKTS:ARTH) and Antares Pharma (NASDAQ:ATRS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.
Volatility and Risk
Arch Therapeutics has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500.
This table compares Arch Therapeutics and Antares Pharma’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Arch Therapeutics||N/A||N/A||-$4.55 million||N/A||N/A|
|Antares Pharma||$123.86 million||3.71||-$2.03 million||($0.01)||-277.00|
Antares Pharma has higher revenue and earnings than Arch Therapeutics.
This table compares Arch Therapeutics and Antares Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and recommmendations for Arch Therapeutics and Antares Pharma, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Arch Therapeutics currently has a consensus target price of $1.38, suggesting a potential upside of 706.45%. Antares Pharma has a consensus target price of $5.63, suggesting a potential upside of 103.07%. Given Arch Therapeutics’ higher possible upside, analysts clearly believe Arch Therapeutics is more favorable than Antares Pharma.
Institutional & Insider Ownership
0.0% of Arch Therapeutics shares are held by institutional investors. Comparatively, 43.0% of Antares Pharma shares are held by institutional investors. 12.2% of Arch Therapeutics shares are held by insiders. Comparatively, 5.9% of Antares Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Antares Pharma beats Arch Therapeutics on 8 of the 10 factors compared between the two stocks.
About Arch Therapeutics
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a product containing synthetic biocompatible peptides that comprise naturally occurring amino acids to achieve hemostasis in skin wounds and in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.
About Antares Pharma
Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.
Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.